13D Filing: Monarch Alternative Capital and Resolute Energy Corp (REN)

---

Pursuant to Rule 13d-2 promulgated under the Act, this Amendment No. 1 to Schedule 13D (this
Amendment No. 1) is being filed with respect to the common stock par value $0.0001 per share (Common Stock), of Resolute Energy Corporation (the Issuer), to amend the Schedule 13D filed
on January 26, 2018 (the Original 13D and, as amended by this Amendment No. 1, the Schedule 13D). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the
Original 13D.

Item 4.

Purpose of Transaction

Item 4 of this Schedule 13D is hereby amended to include the following:

Following discussions with the Issuer after its receipt of the January Letter, the Reporting Persons continue to believe that changes to
the Board are necessary to maximize stockholder value. As a result, on February 8, 2018, an affiliate of the Reporting Persons delivered a nomination notice (the Nomination Notice) to the Issuer which is attached as Exhibit
99.3 to this Schedule 13D, nominating three highly qualified individuals, Patrick Bartels, Joseph Citarrella and Samuel Langford (collectively, the Nominees), for election to the Board at the Issuers 2018 annual meeting of
stockholders (the Annual Meeting).

The Reporting Persons believe that the Nominees have the qualifications, experience
and skill sets that will make them valuable additions to the Board.

The Reporting Persons have engaged, and may continue to engage, in
discussions with the Issuer regarding Board representation and the composition of the Issuers Board, generally.

The Nomination
Notice also includes a notice to the Issuer that the Reporting Persons intend to submit, for a stockholder vote at the Annual Meeting, a resolution that would repeal any provision of the Bylaws of the Issuer in effect at the time of the Annual
Meeting that was not included in the Bylaws of the Issuer in effect as of February 8, 2018 and as publicly filed with the Securities and Exchange Commission (the SEC) prior to February 8, 2018.

Item 5.

Interests in Securities of the Issuer

Item 5(a)-(c) of this Schedule 13D is hereby amended
and restated to read as follows:

(a) Each of MAC, MDRA GP and Monarch GP indirectly beneficially own 2,193,400 shares of Common Stock.
Such shares represent 9.75% of the 22,503,907 common shares outstanding as of October 31, 2017, according to the Form 10-Q filed by the Issuer with the SEC on November 6, 2017. None of the individual Funds beneficially own a number of
shares of Common Stock representing more than 5% of the outstanding shares of Common Stock.

(b) MAC, MDRA GP and Monarch GP share voting
and dispositive power over 2,193,400 shares of Common Stock with each applicable Fund directly holding such shares, except for 100 of such shares, which the Funds hold indirectly through

affiliated entities.